[Progress in the prevention and control of urologic complications of the cervix carcinoma. I. Urinary tract infections].
An investigation was made on patients with cervical carcinoma to test the efficiency of a general administration of antibiotics and chemotherapeutic drugs which are commonly used in urology. The study has been made to analyze the frequency of pathological findings in the urinary tract, in general, and, in particular, the pattern of bacteriological findings as well as antibiogramms at different times of carcinoma therapy. Additionally, consideration was given to the bacteriological situation before the onset of carcinoma therapy and to manifest urologic complications during and after carcinoma therapy. In cases of primary absence of bacteria in urine the therapy preferably used in this clinic was that with chloramphenicol and nifurantin administered up to the 4th week after operation and this was sufficient in two thirds of cases. Conversely, in patients with primary bacteriuria the results of treatment after 4 weeks were satisfactory in only one third of the cases. This poses the necessity of making a more subtle selection of drugs including broad spectrum penicillins. Moreover, therapy has to be continued mainly for women with a previous urological history and for women in whom infections of the urinary tract were observed on release from the hospital. In addition to prevention of chronic pyelonephritis improvement of postoperative wound healing as well as restriction of ureteral fibrosis, hydronephrosis and uremia, as a result of general control of infection are also of considerable importance.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001437:Bacteriuria / Q000517:prevention & control; D004927:Escherichia coli Infections / Q000517:prevention & control; D005260:Female; D006801:Humans; D009582:Nitrofurantoin / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D011512:Proteus Infections / Q000517:prevention & control; D011552:Pseudomonas Infections / Q000517:prevention & control; D014552:Urinary Tract Infections / Q000209:etiology / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000601:surgery
D000900:Anti-Bacterial Agents; D009582:Nitrofurantoin
Fortschritte bei der Verhütung und Bekämpfung urologischer Komplikationen des Zervixkarzinoms. I. Mitteilung: Harnwegsinfektionen